AG Stein

Profil

Informationen zu unserer Arbeitsgruppe finden Sie auf der englischen Seite.

Team

Leiter

Prof. Dr. Ulrike Stein

31.1: Max Delbrück House (Hochbau)

Raum: 4017

ustein@mdc-berlin.de

9406-3432

Senior Wissenschaftler

PD Dr. Wolfgang Kemmner

42-52: Experimental and Clinical Research Center

Raum: Haus 50 Raum 0544

wkemmner@mdc-berlin.de

450-540186

Prof. Dr. Wolfgang Walther

31.1: Max Delbrück House (Hochbau)

Raum: 4017

wowalt@mdc-berlin.de

9406-3432

Wissenschaftler

Dr. Mathias Dahlmann

31.1: Max Delbrück House (Hochbau)

Raum: 4044

dahlmann@mdc-berlin.de

2389

Dr. Dennis Kobelt

31.1: Max Delbrück House (Hochbau)

Raum: 5015.1

dennis.kobelt@mdc-berlin.de

9406-2389

31.1: Max Delbrück House (Hochbau)

Raum: 4044

dennis.kobelt@mdc-berlin.de

9406-3703

Harikrishnan Radhakrishnan

31.1: Max Delbrück House (Hochbau)

Raum: 5014.2

Harikrishnan.Radhakrishnan@mdc-berlin.de

2504

Technischer Assistent

Pia Herrmann

31.1: Max Delbrück House (Hochbau)

Raum: 4045

Pia.Herrmann@mdc-berlin.de

3741

Margarita Mokrizkij

Margarita.Mokrizkij@mdc-berlin.de

Janice Smith

31.1: Max Delbrück House (Hochbau)

Raum: 4044

j.smith@mdc-berlin.de

3703

Doktorand

Müge Erdem

31.1: Max Delbrück House (Hochbau)

Raum: 5014.2

Muege.Erdem@mdc-berlin.de

2504

Francesca Imbastari

31.1: Max Delbrück House (Hochbau)

Raum: 5014.2

Francesca.Imbastari@mdc-berlin.de

31.1: Max Delbrück House (Hochbau)

Raum: 4044

Francesca.Imbastari@mdc-berlin.de

2504

Benedikt Kortüm

31.1: Max Delbrück House (Hochbau)

Raum: 4045

Benedikt.Kortuem@mdc-berlin.de

+49 30 9406 3703

Fabian Zincke

31.1: Max Delbrück House (Hochbau)

Raum: 4045

Fabian.Zincke@mdc-berlin.de

2504

Veröffentlichungen

01. Juli 2018 in Neuroendocrinology

Mechanisms of targeting the MDM2-p53-FOXM1 axis in well-differentiated intestinal neuroendocrine tumors

F. Briest et al.

04. April 2018 in Mol Ther

Efficient non-viral gene delivery into human hematopoietic stem cells by minicircle Sleeping Beauty transposon vectors

M. Holstein et al.

15. März 2018 in BMC Cancer

Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial

S. Burock et al.

01. Februar 2018 in Transl Oncol

Genome-wide analysis of barrett's adenocarcinoma. a first step towards identifying patients at risk and developing therapeutic paths

Y. Dai et al.

27. Dezember 2017 in J Infect Dis

In colon epithelia, Clostridium perfringens enterotoxin causes focal leaks by targeting claudins which are apically accessible due to tight junction derangement

M. Eichner et al.

01. Dezember 2017 in Biochim. Biophys. Acta Rev. Cancer

Approaches and techniques to characterize cancer metabolism in vitro and in vivo

I. Zaimenko et al.

01. Dezember 2017 in Clin Exp Metastasis

Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example

B. Fingleton et al.

10. September 2017 in Canc Lett

MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers

H. Radhakrishnan et al.

01. August 2017 in Ann Oncol

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies

U.P. Rohr et al.

01. Juni 2017 in PLoS Biol

Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1

M. Juneja et al.

Nachrichten

Pressemitteilung Nr. 15 26. Juli 2017 Berlin

Biomarker zeigen Aggressivität des Tumors an